Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Subjects have a type of cancer called Hodgkin Disease (HD), a cancer of the lymph system. The
lymph system is made up of tissue throughout the body that makes and stores
infection-fighting cells. HD is one of the most treatable childhood cancers. The standard
treatment for HD involves chemotherapy (treatment with anti-cancer drugs) and radiation
therapy (the use of high-dose x-rays to get rid of cancer cells). Although they are cured
from their cancer, some patients experience negative side effects from treatment later in
life. These kinds of side effects are often referred to as late effects. This can include
problems with growth, problems with some organ functions, and sometimes second cancers. These
types of effects can be associated with either chemotherapy or radiation therapy. The
investigators are therefore designing studies to minimize or prevent these late effects. It
is thought that if some patients can be successfully treated without radiation, those
patients might experience fewer late side effects.
Some patients, however, do not respond as well to the first stages of treatment (slow early
responders). Slow early responders are considered to be at higher risk for relapse. This
study also looks at whether these kinds of patients will benefit from additional
chemotherapy.
The purpose of this study is to look at how the immune system recovers and at how certain
T-cells in the blood behave after receiving chemotherapy with or without radiation. The
investigators also want to identify if bio-markers (special proteins in blood and in cancer)
relate to the response of HD to study treatment.